First human trial tests 'Rejuvenating' gene therapy for blinding eye diseases
Disease control
Recruiting now
This is the first study in people to test the safety of a new gene therapy called ER-100 for two conditions that damage the optic nerve and cause vision loss: open-angle glaucoma and NAION. Researchers will give a single dose to 18 adults and closely monitor them for side effects…
Phase: PHASE1 • Sponsor: Life Biosciences Inc. • Aim: Disease control
Last updated Mar 25, 2026 14:07 UTC